WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO2007000764) COMPOSITIONS AND METHODS FOR ENHANCEMENT OF SEXUAL FUNCTION
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, the composition being such that an efficacy window of said an erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap.

2. A pharmaceutical composition comprising a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, the composition being such that said erection-enhancing agent and said ejaculation-delaying agent act in synergy.

3. The pharmaceutical composition of claim 2, wherein said pharmaceutically effective amount of said erection-enhancing agent equals to or is lower than 25 mg per dosage unit.

4. The pharmaceutical composition of claim 3, wherein said pharmaceutically effective amount of said ejaculation-delaying agent is lower than 50 mg per dosage unit.

5. A pharmaceutical composition comprising clomipramine, as an ejaculation-delaying agent, and a PDE5 inhibitor, as an erection enhancing agent

6. The pharmaceutical composition of any of claims 1-5, being such that a maximal efficacy window of said erection-enhancing agent and a maximal efficacy window of said ejaculation-delaying agent overlap for at least 20 minutes.

7. The pharmaceutical composition of any of claims 1-5, being designed such that a plasma peak concentration of said ejaculation-delaying agent and a plasma peak concentration of said erection-enhancing agent occur substantially simultaneously.

8. The pharmaceutical composition of any of claims 1-5, wherein at least said erection-enhancing agent is provided in a delayed release form.

9. The pharmaceutical composition of any of claims 1 to 4 and 6 to 8, wherein said ejaculation-delaying agent is clomipramine.

10. The pharmaceutical composition of any of claims 1 to 4 and 6 to 9, wherein said erection-enhancing agent is selected from the group consisting of a phosphodiesterase type 5 inhibitor, arginine and human DNA.

11. The pharmaceutical composition of any of claims 5 and 9, wherein said erection-enhancing agent is a phosphodiesterase type 5 inhibitor selected from the group consisting of tadalafil, vardenafϊl and sildenafil.

12. The pharmaceutical composition of claim 11, being formulated as a pharmaceutical dosage unit.

13. The pharmaceutical composition of claim 12, wherein an amount of said clomipramine ranges from about 15 mg to about 30 mg per dosage unit.

14. The pharmaceutical composition of claim 12, wherein said erection-enhancing agent comprises tadalafil or vardenafϊl.

15. The pharmaceutical composition of claim 14, wherein an amount of said erection-enhancing agent ranges from about 10 mg to about 20 mg per dosage unit.

16. The pharmaceutical composition of claim 14, wherein an amount of said erection-enhancing agent is about 10 mg.

17. The pharmaceutical composition of claim 12, wherein said erection-enhancing agent comprises sildenafil.

18. The pharmaceutical composition of claim 17, wherein an amount of said sildenafil is about 25 mg per dosage unit.

19. The pharmaceutical composition of any of claims 1-18, being provided in a delivery form suitable for oral administration.

20. A method of enhancing sexual satisfaction, the method comprising coadministering a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, such that an efficacy window of said erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap, thereby enhancing sexual dysfunction.

21. A method of enhancing sexual satisfaction, the method comprising co-administering a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, said erection-enhancing agent and said ejaculation-delaying agent acting in synergy, thereby enhancing sexual dysfunction.

22. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein an efficacy window of said erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap, for the preparation of a medicament for enhancing sexual satisfaction.

23. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein said erection-enhancing agent and said ejaculation-delaying acting in synergy, for the preparation of a medicament for enhancing sexual satisfaction.

24. A method of treating erectile dysfunction, the method comprising coadministering to a subject in need thereof a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, such that an efficacy window of said an erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap, thereby treating erectile dysfunction.

25. A method of treating erectile dysfunction, the method comprising coadministering to a subject in need thereof a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, said erection-enhancing agent and said ejaculation-delaying agent acting in synergy, thereby treating erectile dysfunction.

26. A method of treating erectile dysfunction, the method comprising co-administering to a subject in need thereof a pharmaceutically effective amount of a phosphodiesterase type 5 inhibitor, as an erection-enhancing agent and a pharmaceutically effective amount of clomipramine, as an ejaculation-delaying agent, thereby treating erectile dysfunction.

27. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein an efficacy window of said erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap, for the preparation of a medicament for treating erectile dysfunction.

28. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein said erection-enhancing agent and said ejaculation-delaying agent act in synergy, for the preparation of a medicament for treating erectile dysfunction.

29. Use of a phosphodiesterase type 5 inhibitor as an erection-enhancing agent and clomipramine as an ejaculation-delaying agent, for the preparation of a medicament for treating erectile dysfunction.

30. A method of treating sexual dysfunction, the method comprising substantially simultaneously co-administering to a subject in need thereof a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, such that an efficacy window of said an erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap.

31. A method of treating sexual dysfunction, the method comprising substantially simultaneously co-administering to a subject in need thereof a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, said an erection-enhancing agent and said ejaculation-delaying agent acting in synergy, thereby treating sexual dysfunction.

32. A method of treating sexual dysfunction, the method comprising coadministering to a subject in need thereof a pharmaceutically effective amount of a phosphodiesterase type 5 inhibitor as an erection-enhancing agent and a pharmaceutically effective amount of clomipramine as an ejaculation-delaying agent.

33. The method of claim 32, wherein said co-administering is performed substantially simultaneously.

34. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein an efficacy window of said erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap, for the preparation of a medicament for treating sexual dysfunction.

35. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein said erection-enhancing agent and said ejaculation-delaying agent acting in synergy, for the preparation of a medicament for treating sexual dysfunction.

36. Use of a phosphodiesterase type 5 inhibitor as an erection-enhancing agent and clomipramine as an ejaculation-delaying agent, for the preparation of a medicament for treating sexual dysfunction.

37. A method of treating ejaculatory dysfunction caused by treatment with an agent for the treatment of erectile dysfunction, the method comprising substantially simultaneously co-administering to a subject in need thereof a pharmaceutically effective amount of an erection-enhancing agent and a pharmaceutically effective amount of an ejaculation-delaying agent, such that an efficacy window of said an erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap.

38. Use of an erection-enhancing agent and an ejaculation-delaying agent, wherein an efficacy window of said erection-enhancing agent and an efficacy window of said ejaculation-delaying agent substantially overlap, for the preparation of a medicament for treating ejaculatory dysfunction caused by treatment with an agent for the treatment of erectile dysfunction.

39. The method or use of any of claims 24 to 28, wherein said erectile dysfunction is caused by treatment with an ejaculation-delaying agent.

40. The method or use of any of claims 21, 23, 25, 26, 28, 29, 31 and 32, wherein said pharmaceutically effective amount of said erection-enhancing agent equals to or is lower than 20 mg per dosage unit.

41. The method or use of claim 40, wherein said pharmaceutically effective amount of said ejaculation-delaying agent is lower than 50 mg per dosage unit.

42. The method or use of any of claims 20 to 38, wherein said ejaculation-delaying agent is clomipramine.

43. The method or use of any of claims 20 to 38, wherein said erection-enhancing agent is a phosphodiesterase type 5 inhibitor.

44. The method or use of claim 43, wherein said phosphodiesterase type 5 inhibitor is selected from the group consisting of tadalafil, vardenafil and sildenafil.

45. The method of claim 44, wherein said ejaculation-delaying agent is clomipramine.

46. The method of any of claims 20, 24, 30 and 37, wherein said administering is effected orally.

47. The method or use of any of claims 20 to 38, wherein said erection-enhancing agent and said ejaculation-delaying agent are provided as a single dosage unit.

48. The method or use of any of claims 20 to 38, wherein said erection-enhancing agent and said ejaculation-delaying agent are provided as separate dosage units.